Interferon-beta - CytoCure
Latest Information Update: 13 Sep 2023
Price :
$50 *
At a glance
- Originator CytoCure
- Class Antineoplastics; Antivirals; Interferons; Skin disorder therapies
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 13 Sep 2023 Interferon-beta is still in preclinical trials for Malignant-melanoma (Combination therapy) in USA (CytoCure website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Malignant-melanoma(Combination therapy) in USA
- 02 Aug 2016 Preclinical trials in Malignant melanoma (Combination therapy) in USA (unspecified route)